VENUS

Dove and Nike Team Up to Launch BODY CONFIDENT SPORT, a First-of-its-Kind Online Coaching Program to Help Build Body Confidence in Girls Globally

Retrieved on: 
Tuesday, October 24, 2023
Venus, Woman, Research, Sport, CAR, Pressure, Face, Gold, Gold medal, Nike, Athlete, Environment, VENUS, Partnership, School, Love, Body, Hearing, Toy, Tutoring, Columbidae

ENGLEWOOD CLIFFS, N.J., Oct. 24, 2023 /PRNewswire/ -- Girls who participate in physical activity – and stay with it through adolescence – are more likely to have higher body confidence and experience benefits throughout their lives. However, NEW research from Dove and Nike reveals 45% of teenage girls globally drop out of sports - at twice the rate of boys - with low body confidence as the biggest driver.

Key Points: 
  • However, NEW research from Dove and Nike reveals 45% of teenage girls globally drop out of sports - at twice the rate of boys - with low body confidence as the biggest driver.
  • For the first time ever, Dove – the world's largest provider of self-esteem and body confidence education – has teamed up with Nike – the biggest champion of athletes and sports – to launch the Body Confident Sport online coaching program.
  • Body Confident Sport is a first-of-its-kind, scientifically-proven set of coaching tools to build body confidence in 11–17-year-old girls.
  • According to the new findings from Dove and Nike, the sports environment impacts girls' body confidence and self-esteem:
    51% of girls dropping out were told that they are not good enough.

SAN ANTONIO TO HOST INTERNATIONAL TEAM TENNIS CHAMPIONSHIPS FEATURING TOP ATP WTA STARS NOVEMBER 10-12

Retrieved on: 
Tuesday, July 11, 2023
Venus, Sport, Austin Capitals, Trinity, UTPB, SA Sports Badge, ATP, VENUS, UTSA, Woman, J. J. Wolf, WTA, Sale, Freeman Coliseum, Frost, San Antonio Sporting District, SAN, Texas A&M University, KYIV, Nightclub, Sports equipment, University of Texas at Austin

SAN ANTONIO, July 11, 2023 /PRNewswire/ -- San Antonio Sports announced today the inaugural San Antonio International Team Tennis Championships presented by Frost, H-E-B and SA Sports. Featuring ten ATP & WTA professionals, the event will be hosted by Freeman Coliseum November 10-12, 2023.

Key Points: 
  • SAN ANTONIO, July 11, 2023 /PRNewswire/ -- San Antonio Sports announced today the inaugural San Antonio International Team Tennis Championships presented by Frost, H-E-B and SA Sports.
  • The San Antonio International Team Tennis Championships will feature two teams consisting of top ATP & WTA players, college players and top ranked Texas junior players.
  • "The San Antonio International Team Tennis Championships will provide tennis fans the opportunity to see world class tennis at the only professional event in Texas to feature both top ranked men and women professionals."
  • For more information on the San Antonio International Team Tennis Championships, please visit www.sanantonioitc.com .

Venus Beings Contacted USSR in 1966, Claim New Documents Leaked in THE VENUS INTERCEPT by V.S. Marlowe

Retrieved on: 
Tuesday, February 21, 2023
Science, Telepathy, Religion, Soviet people, Communist party, Head, Astronomy, KGB, Intelligence, Teleportation, VENUS, Interview, Venera, Multimedia

Marlowe's THE VENUS INTERCEPT: TZINTZUNTZAN -- a sequel to his visionary 2019 book THE SERPENT'S THRONE -- leaks Soviet documents from the 1960s and 70s showing that advanced beings on or near Venus contacted the early Soviet Venera 3 probe before it crashed on the planet in 1966.

Key Points: 
  • Marlowe's THE VENUS INTERCEPT: TZINTZUNTZAN -- a sequel to his visionary 2019 book THE SERPENT'S THRONE -- leaks Soviet documents from the 1960s and 70s showing that advanced beings on or near Venus contacted the early Soviet Venera 3 probe before it crashed on the planet in 1966.
  • According to the documents, the contact triggered a 15 year crash Soviet program to learn from the aliens, including efforts in teletransportation, telepathy and parallel realities.
  • An expatriate US energy trader who seems to be in contact with the aliens is being used by both sides."
  • Marlowe, call him on Skype at VSMarlowe, by phone at +1 347 509 4221 or by email at [email protected] .

Nouscom's Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors

Retrieved on: 
Monday, November 7, 2022
Blood, Neoplasm, Journal, RECIST, VENUS, Time, 2021 Essex County Council election, JITC, Lead, SAIDI, Safety, NSCLC, Gad, Bristol Myers Squibb, Vaccine, Large-cell lung carcinoma, Immunotherapy, MVA, Annual general meeting, Accuracy and precision, Janssen Pharmaceuticals, Immune system, Pembrolizumab, Myeloproliferative neoplasm, Development, Melanoma, Society, SITC, GMP, Patient, MD, Cancer, Department, Society for Immunotherapy of Cancer, Pharmaceutical industry

BASEL, Switzerland, Nov. 7, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced interim data from the Phase 1b trial evaluating NOUS-PEV which demonstrated it to be safe, well tolerated, immunogenic and with signs of anti-tumor activity. These data will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12, 2022.

Key Points: 
  • NOUS-PEV is a personalized cancer immunotherapy being evaluated in a multicenter Phase 1b open-label, dose confirmation and cohort expansion study (NCT04990479).
  • NOUS-PEV is individually designed and manufactured to contain patient-specific neoantigens identified and selected from a patient's own tumor biopsy.
  • The data demonstrated NOUS-PEV to be well tolerated and to have a good safety profile, comparable to pembrolizumab monotherapy.
  • NOUS-PEV is a personalized cancer immunotherapy designed for each patient based on selection and prioritization of mutations unique to that patient's tumor.

Nouscom's Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors

Retrieved on: 
Monday, November 7, 2022
Blood, Neoplasm, Journal, RECIST, VENUS, Time, 2021 Essex County Council election, JITC, Lead, SAIDI, Safety, NSCLC, Gad, Bristol Myers Squibb, Vaccine, Large-cell lung carcinoma, Immunotherapy, MVA, Annual general meeting, Accuracy and precision, Janssen Pharmaceuticals, Immune system, Pembrolizumab, Myeloproliferative neoplasm, Development, Melanoma, Society, SITC, GMP, Patient, MD, Cancer, Department, Society for Immunotherapy of Cancer, Pharmaceutical industry

BASEL, Switzerland, Nov. 7, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced interim data from the Phase 1b trial evaluating NOUS-PEV which demonstrated it to be safe, well tolerated, immunogenic and with signs of anti-tumor activity. These data will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12, 2022.

Key Points: 
  • NOUS-PEV is a personalized cancer immunotherapy being evaluated in a multicenter Phase 1b open-label, dose confirmation and cohort expansion study (NCT04990479).
  • NOUS-PEV is individually designed and manufactured to contain patient-specific neoantigens identified and selected from a patient's own tumor biopsy.
  • The data demonstrated NOUS-PEV to be well tolerated and to have a good safety profile, comparable to pembrolizumab monotherapy.
  • NOUS-PEV is a personalized cancer immunotherapy designed for each patient based on selection and prioritization of mutations unique to that patient's tumor.

FDA Clears SeptiCyte® RAPID - The First One-Hour, Direct-from-Blood Sepsis Test

Retrieved on: 
Tuesday, November 30, 2021
Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ageing, Technology, Industry, Falls, Hospital, PCR, Diagnosis, Partnership, MDX, Prevalence, Polymerase, Gene expression, Inflammation, University, NEPTUNE, Cohort study, Disease, Mark (given name), Polymerase chain reaction, Euronext, COVID 19, Vital signs, Physician, ICU, Fever, Melanoma, Twitter, Near, Incidence, Rush University, COVID, Mycosis, FDA, Mortality, CE marking, Infection, VENUS, Food, Emory University, Medical device, Vaccine, Medical imaging, Pharmaceutical industry

The cleared test is an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalized patients suspected of sepsis.

Key Points: 
  • The cleared test is an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalized patients suspected of sepsis.
  • SeptiCyte RAPID will be the first FDA cleared test to differentiate sepsis from non-infectious systemic inflammation to aid in a sepsis diagnosis within approximately one hour for patients suspected of sepsis.
  • As of November 2021, SeptiCyte RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis.
  • SeptiCyte RAPID is a lab test for sepsis that combines SeptiCyte technology with the Biocartis' Idylla platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis; diagnosing bacterial sepsis, viral sepsis, or fungal infections.

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

Retrieved on: 
Tuesday, August 10, 2021
CD4, VENUS, Immunotherapy, Neoplasm, CD8, Cancer, Peptide, Accuracy and precision, NSCLC, Melanoma, Patient, MSI, LinkedIn, Veteran, MVA, Large-cell lung carcinoma, Research, Gad, Pharmaceutical industry, Vaccine

BASEL, Switzerland, Aug, 10, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announces the online publication of new research describing its novel and proprietary algorithm for the identification and prioritization of patient-specific tumor neoantigens, VENUS.   

Key Points: 
  • The VENUS algorithm predicts tumor specific mutated peptides that have the highest likelihood of inducing an immune responseand act as neoantigens.
  • NOUS-PEV is a personalized cancer immunotherapy designed for each patient based on selection and prioritization of mutations unique to that patient's tumor.
  • Nouscom is headquartered in Basel, Switzerland with operations in Rome, Italy, and is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

Retrieved on: 
Tuesday, August 10, 2021
CD4, VENUS, Immunotherapy, Neoplasm, CD8, Cancer, Peptide, Accuracy and precision, NSCLC, Melanoma, Patient, MSI, LinkedIn, Veteran, MVA, Large-cell lung carcinoma, Research, Gad, Pharmaceutical industry, Vaccine

BASEL, Switzerland, Aug, 10, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announces the online publication of new research describing its novel and proprietary algorithm for the identification and prioritization of patient-specific tumor neoantigens, VENUS.   

Key Points: 
  • The VENUS algorithm predicts tumor specific mutated peptides that have the highest likelihood of inducing an immune responseand act as neoantigens.
  • NOUS-PEV is a personalized cancer immunotherapy designed for each patient based on selection and prioritization of mutations unique to that patient's tumor.
  • Nouscom is headquartered in Basel, Switzerland with operations in Rome, Italy, and is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/